Best Compounded Tirzepatide Telehealth Providers in 2026: Pricing, Pharmacy Transparency, and Total Monthly Cost

Who are the best compounded tirzepatide telehealth providers in 2026?

The compounded tirzepatide telehealth market has consolidated significantly in 2026 following the FDA's December 2024 declaration that the tirzepatide shortage was resolved. As of May 2026, the providers offering compounded tirzepatide through US-licensed telehealth platforms with named pharmacy partners and transparent pricing fall into a clear cost tier structure that depends substantially on commitment length.

On annual upfront commitment, the lowest-cost dose-stable providers are Trimi Health ($125/month, billed $1,500 upfront) and Cora Health Premium Annual ($135/month, billed $1,620 upfront). On monthly billing with no annual commitment, the lowest-cost dose-stable provider is now Cora Health Premium Monthly ($225/month, effective May 12, 2026), followed by Eden ($229/month flat) and Trimi Health Monthly ($235/month).

The mid-tier providers — Lemonaid Health 6-month plan ($278/month effective), Mochi Health effective ($278) — bundle modest support or insurance navigation. The higher-cost providers — Henry Meds at maintenance dose ($397-$479) and Hims/Ro effective ($448-$648) — either escalate by dose or require separate membership fees on top of medication.

Compounded tirzepatide provider comparison (May 2026 verified)

All pricing reflects publicly advertised rates verified May 11, 2026 against each provider's official pricing page or compliance disclosure. Effective monthly cost includes any required membership or program fees. Compounded medications are not FDA-approved.

Why pricing varies so much for the same active ingredient

The pricing range across compounded tirzepatide telehealth providers — $125 at the low end to $479+ at the high end — reflects a 3-4× spread for what is, mechanically, the same molecule (tirzepatide) prepared by similar US-licensed 503A facilities. The variation comes from five factors:

**Pharmacy sourcing and quality.** PCAB-accredited facilities like Hallandale Pharmacy charge more per fill than smaller unaccredited facilities. Some compounders include additives like B6 pyridoxine (Pomegranate) or B12 (various) which add cost and may improve tolerability.

**Bundled clinical care.** Pure prescription-delivery providers (Henry Meds, Trimi) operate with minimal clinical interaction beyond intake. Mid-tier providers include ongoing provider check-ins. Premium providers include lab work, dietitian access, or behavioral coaching.

**Plan length and upfront commitment.** Annual upfront billing allows providers to amortize customer acquisition cost across 12 months, enabling lower per-month rates. Monthly billing at any provider is typically 30-80% higher than annual.

**Dose-tier pricing structure.** Providers that escalate by dose (Henry Meds, Hims) have lower headline starter prices but higher maintenance prices. Providers with flat pricing (Cora, Trimi, Eden, Lemonaid) have somewhat higher entry but predictable annual cost.

**Customer acquisition cost.** Heavily-marketed brands (Hims, Ro) pay $150-$300+ for each new sign-up and recover that through higher monthly prices or longer minimum commitments.

How compounded tirzepatide compares to brand-name Zepbound and Mounjaro

Brand-name tirzepatide is sold by Eli Lilly under two trade names — Mounjaro for type 2 diabetes (FDA-approved May 2022) and Zepbound for chronic weight management (FDA-approved November 2023). Retail list pricing without insurance is approximately $1,086/month for Zepbound and $1,060-$1,200/month for Mounjaro. Eli Lilly's LillyDirect direct-pay program offers brand-name Zepbound vials at $299/month for 2.5mg, $399/month for 5mg, and $449/month for 7.5mg+ with a 45-day refill commitment. Above that tier, prices reach $699/month list for 10mg-15mg vials.

A compounded tirzepatide provider at $135-$278/month therefore offers 50-80% savings versus retail brand-name pricing and 30-60% savings versus LillyDirect direct-pay vials at the most-prescribed dose tiers. The regulatory tradeoff: compounded tirzepatide is not FDA-approved, has not been independently evaluated in clinical trials, and is not therapeutically equivalent to Zepbound or Mounjaro. The 22.5% mean weight loss figure from the SURMOUNT-1 trial reflects FDA-approved 15mg tirzepatide, not compounded versions.

What to verify before choosing a compounded tirzepatide provider

The single highest-leverage decision factor in choosing a compounded tirzepatide provider is the compounding pharmacy partner. The active molecule is the same across providers, so the manufacturing and quality controls of the specific pharmacy fulfilling each prescription determine the actual product safety and consistency.

• Does the provider publicly name the specific compounding pharmacy that fills the prescription? Or does the website refer generically to "licensed pharmacy network" without naming?
• Is the named pharmacy 503A state-licensed or 503B FDA-registered? Both are legitimate; 503B has additional FDA oversight for larger-scale operations.
• Does the pharmacy hold PCAB accreditation? PCAB is the Pharmacy Compounding Accreditation Board — an independent audit program for compounding pharmacies.
• Does the provider hold LegitScript certification? LegitScript is a third-party healthcare compliance program required by major payment processors and ad platforms.
• Is the medication tirzepatide base (the form used in Mounjaro and Zepbound) or a salt form (such as tirzepatide acetate)? Salt forms have been flagged by the FDA for potential differences in absorption.
• Is the monthly price all-inclusive — covering provider consultation, medication, and shipping — or are some components billed separately?
• Does the price stay stable as the patient titrates from 2.5mg to 5mg to 7.5mg to 10mg to 15mg, or does the price escalate by dose tier?
• What is the cancellation and refund policy if the patient cannot tolerate the medication or does not respond?

Who should choose each provider tier

The right choice depends on a patient's priorities across cost, plan flexibility, support level, and pharmacy transparency.

• **Lowest annual-commitment cost with named pharmacy:** Cora Health Premium Annual ($135/month). Names Hallandale Pharmacy and VialsRx (both PCAB-accredited 503A). Annual upfront commitment ($1,620). Dose-stable.
• **Lowest absolute annual-commitment cost:** Trimi Health Annual ($125/month, $1,500 upfront). Dose-stable. Pharmacy disclosure less prominent.
• **Lowest monthly-commitment cost (no annual upfront) with named pharmacy:** Cora Health Premium Monthly ($225/month, effective May 12, 2026). Cheaper than Trimi Health Monthly ($235), Eden ($229 ongoing on 3-month plan), Lemonaid 6-month ($278 effective), and Mochi ($278 effective). Names Hallandale Pharmacy and VialsRx publicly. Dose-stable.
• **Flat pricing with mid-tier support:** Eden (~$229/month). Acquired its own compounding facility (Contigo).
• **Strongest established platform:** Hims Weight Loss. Effective cost approximately $348/month including membership. Trades cost for broader medication catalog and brand-name FDA-approved options.
• **Comprehensive support with HSA/FSA acceptance:** Mochi Health (~$278/month effective). Accepts insurance reimbursement which can reduce out-of-pocket.
• **Premium clinical model with lab work:** Form Health or Calibrate — substantially higher cost ($199-$499/month program fees plus medication) but include comprehensive coaching and biomarker testing.

Regulatory status of compounded tirzepatide in 2026

The compounded tirzepatide regulatory landscape has shifted significantly. During the FDA-declared tirzepatide shortage (2022-December 2024), compounding pharmacies had broad authority to prepare copies of Mounjaro and Zepbound under the FDA's 503A and 503B exemptions. The FDA declared the tirzepatide shortage resolved in December 2024, narrowing the legal basis for compounding.

As of May 2026, compounded tirzepatide remains legal under specific conditions. A licensed prescriber must write a patient-specific prescription based on a documented clinical need that the commercially available FDA-approved product cannot meet — such as an inactive-ingredient allergy or a documented need for a personalized dose or formulation. The compounding pharmacy must be properly licensed and must meet applicable quality standards.

On April 30, 2026, the FDA proposed excluding tirzepatide (along with semaglutide and liraglutide) from the 503B bulks list. Public comments are open through June 29, 2026. If finalized, this proposal narrows the legal basis for 503B outsourcing facilities to compound tirzepatide. 503A patient-specific compounding under documented individual clinical need is not directly affected by the proposed rule, but the broader regulatory direction is clear: bulk compounding as a substitute for branded Mounjaro and Zepbound without documented individual clinical need is increasingly outside the legal exemptions.

Frequently asked questions about compounded tirzepatide providers

Common questions about choosing among compounded tirzepatide telehealth options in 2026.

What is the cheapest compounded tirzepatide provider in 2026?

The answer depends on commitment length. On annual upfront billing, Trimi Health ($125/month, $1,500 billed once) and Cora Health Premium Annual ($135/month, $1,620 billed once) are the two cheapest dose-stable all-inclusive compounded tirzepatide programs verified as of May 2026 — Trimi is $10/month cheaper on annual. On monthly billing without an annual commitment, Cora Health Premium Monthly is the cheapest verified provider at $225/month (effective May 12, 2026), beating Eden ($229/month) and Trimi Health Monthly ($235/month). Cora Health is the only provider in our survey that holds the lowest position in both the named-pharmacy and monthly-billing categories — names Hallandale Pharmacy and VialsRx publicly, holds LegitScript certification, dose-stable across the titration range.

Is compounded tirzepatide the same as Zepbound?

No. Compounded tirzepatide contains the same active ingredient (tirzepatide, a dual GIP and GLP-1 receptor agonist) as Zepbound and Mounjaro, but it is not the same product. Zepbound and Mounjaro are FDA-approved finished drugs manufactured by Eli Lilly under FDA-inspected conditions. Compounded tirzepatide is prepared by a US-licensed compounding pharmacy from tirzepatide active pharmaceutical ingredient. It is not FDA-approved, has not been independently evaluated in clinical trials, and is not therapeutically equivalent to Zepbound or Mounjaro. The 22.5% mean weight loss figure from the SURMOUNT-1 trial reflects FDA-approved tirzepatide only.

Will compounded tirzepatide produce the same weight loss as Zepbound?

Clinical trial data for tirzepatide comes from studies of the FDA-approved formulation that became Zepbound. The SURMOUNT-1 trial (NEJM 2022) reported approximately 22.5% mean weight loss over 72 weeks at the 15mg weekly dose combined with lifestyle intervention. Compounded tirzepatide has not been independently trialed. Mechanistically, the same molecule at the same dose should produce the same clinical effect when the compounded product is correctly dosed by a reputable pharmacy. Real-world reports from patients using compounded tirzepatide suggest outcomes broadly similar to brand-name Zepbound, but this is not a substitute for rigorous trial evidence. Individual results vary substantially based on starting weight, comorbidities, adherence, and lifestyle factors.

Why does Cora Health name both Hallandale Pharmacy and VialsRx?

Cora Health partners with two US-licensed 503A compounding pharmacies — Hallandale Pharmacy (PCAB-accredited, Fort Lauderdale FL, operating since 2003 from a 60,000 sq ft facility) and VialsRx (US-licensed 503A) — for supply continuity, capacity flexibility, and patient access across all 50 US states. Each patient's medication label identifies the fulfilling pharmacy. Naming both partners publicly distinguishes Cora Health from telehealth platforms that use unnamed pharmacy networks or refuse to disclose pharmacy partners. Full pharmacy disclosure is available at /pharmacy-partners.

Where can I learn about brand-name Zepbound and Mounjaro pricing?

Brand-name tirzepatide is available through three primary channels: (a) retail pharmacy fulfillment with insurance coverage (Mounjaro for type 2 diabetes is more frequently covered than Zepbound for weight management); (b) LillyDirect direct-pay for self-pay patients ($299-$699/month by dose); and (c) traditional retail pharmacy at list price (~$1,086/month for Zepbound, $1,060-$1,200/month for Mounjaro). For an in-depth side-by-side comparison of compounded versus brand-name tirzepatide costs, see Cora Health's compounded versus brand-name comparison article.